Rhythm Pharmaceuticals (RYTM) Tops Q2 EPS by 7c

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q2 EPS of ($0.89), $0.07 better than the analyst estimate of ($0.96). Revenue for the quarter came in at $9.07 million versus the consensus estimate of $2.57 million.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Lumentum shares rise on analyst upgrades, AI demand outlook
• Circle Internet stock climbs on TD Cowen upgrade, Fed rate hike